IDEAYA Biosciences, Inc. (FRA:30J)
Germany
· Delayed Price · Currency is EUR 29.40
+0.60 (2.08%)
Last updated: Dec 4, 2025, 8:05 AM CET
IDEAYA Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Revenue | 214.83 | 7 | 23.39 | 50.93 | 27.94 | 19.54 | Upgrade
|
| Revenue Growth (YoY) | 5377.66% | -70.07% | -54.09% | 82.28% | 43.01% | - | Upgrade
|
| Cost of Revenue | 368.29 | 294.67 | 129.51 | 89.54 | 58.16 | 39.7 | Upgrade
|
| Gross Profit | -153.45 | -287.67 | -106.12 | -38.61 | -30.22 | -20.16 | Upgrade
|
| Selling, General & Admin | 55.43 | 39.3 | 28.31 | 23.9 | 20.05 | 15.18 | Upgrade
|
| Operating Expenses | 55.43 | 39.3 | 28.31 | 23.9 | 20.05 | 15.18 | Upgrade
|
| Operating Income | -208.88 | -326.98 | -134.43 | -62.5 | -50.27 | -35.34 | Upgrade
|
| Interest & Investment Income | 24.91 | 29.27 | 9.92 | 3.15 | 2.34 | 0.83 | Upgrade
|
| EBT Excluding Unusual Items | -183.97 | -297.71 | -124.51 | -59.35 | -47.93 | -34.51 | Upgrade
|
| Gain (Loss) on Sale of Investments | 23.23 | 23.23 | 11.55 | 0.7 | -1.83 | 0.02 | Upgrade
|
| Pretax Income | -160.74 | -274.48 | -112.96 | -58.66 | -49.76 | -34.5 | Upgrade
|
| Net Income | -160.74 | -274.48 | -112.96 | -58.66 | -49.76 | -34.5 | Upgrade
|
| Net Income to Common | -160.74 | -274.48 | -112.96 | -58.66 | -49.76 | -34.5 | Upgrade
|
| Shares Outstanding (Basic) | 88 | 82 | 58 | 41 | 35 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 88 | 82 | 58 | 41 | 35 | 25 | Upgrade
|
| Shares Change (YoY) | 15.78% | 42.00% | 38.79% | 17.57% | 42.60% | 97.82% | Upgrade
|
| EPS (Basic) | -1.82 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | Upgrade
|
| EPS (Diluted) | -1.82 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | Upgrade
|
| Free Cash Flow | -105.39 | -251.44 | -117.59 | -90.62 | -58.42 | 54.97 | Upgrade
|
| Free Cash Flow Per Share | -1.20 | -3.08 | -2.04 | -2.19 | -1.66 | 2.22 | Upgrade
|
| Gross Margin | -71.43% | - | - | -75.80% | -108.15% | -103.18% | Upgrade
|
| Operating Margin | -97.23% | -4671.07% | -574.85% | -122.72% | -179.91% | -180.90% | Upgrade
|
| Profit Margin | -74.82% | -3921.10% | -483.05% | -115.17% | -178.10% | -176.55% | Upgrade
|
| Free Cash Flow Margin | -49.06% | -3592.01% | -502.85% | -177.92% | -209.09% | 281.35% | Upgrade
|
| EBITDA | -206.33 | -324.59 | -131.95 | -60.4 | -48.54 | -33.96 | Upgrade
|
| EBITDA Margin | -96.04% | - | - | -118.59% | -173.73% | -173.83% | Upgrade
|
| D&A For EBITDA | 2.55 | 2.39 | 2.48 | 2.1 | 1.73 | 1.38 | Upgrade
|
| EBIT | -208.88 | -326.98 | -134.43 | -62.5 | -50.27 | -35.34 | Upgrade
|
| EBIT Margin | -97.23% | - | - | -122.72% | -179.91% | -180.90% | Upgrade
|
| Revenue as Reported | 214.83 | 7 | 23.39 | 50.93 | 27.94 | 19.54 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.